Search Thermo Fisher Scientific
- Order Status
- Quick Order
-
Don't have an account ? Create Account
ProcartaPlex Kidney Toxicity Panels
Toxicity is crucial in biological research and plays an important role in drug development. Toxicity studies aim to remove toxic compounds early in the drug development process, as drug-induced toxicities are the leading cause of drug failures.
Organ-specific toxicity tests—specifically the kidney—are of high interest as a central detoxification organ for their high exposure to drugs, reactive metabolites, and environmental chemicals. Kidney toxicity is routinely assessed during preclinical safety evaluations.
Nephrotoxicity research meets ProcartaPlex Multiplex Immunoassays
Invitrogen ProcartaPlex immunoassays for kidney toxicity enable the simultaneous quantification of up to 11 targets in a single well. These assays are available as single targets, preconfigured panels of targets, and custom-blended Mix & Match panels.
- Measure multiple biomarkers—analyze up to 11 toxicity targets (including FDA-recommended biomarkers*) at the same time
- Use several sample types—optimized for urine, serum/plasma, or cell culture supernatant samples
- Profile more biomarkers with less sample—multiple biomarkers in the same well means less sample input
Analyze up to 11 toxicity targets at the same time
Simultaneous detection of these targets can help to gain more information about kidney functions and nephrotoxicity during drug development studies.
Click image to enlarge
Figure 1. Urinary marker in Acute Kidney Injury (AKI) and Renal Kidney Failure (RKF) vs. control samples. Significantly increased protein markers in samples from individuals with Acute Kidney Injury/Renal Kidney Failure vs. Controls. 37 urine samples were tested including 14 Controls, 10 Acute Kidney Injury (AKI), 13 Renal Kidney Failure (RKF) samples using the Human Kidney Toxicity 11-plex ProcartaPlex Panel 1.
Click image to enlarge
Figure 2. Urinary marker in Acute Kidney Injury (AKI) and Renal Kidney Failure (RKF) vs. control sample. 40 urine samples of subjects with chronic kidney disease of uncertain etiology (CKDu) and 12 controls were tested with ProcartaPlex Human Kidney Toxicity 9-plex Panel 2. The concentration of 10 markers were significantly increased compared with samples of healthy donors.
Ordering Information
Preconfigured ProcartaPlex multiplex immunoassay panels for nephrotoxicity
ProcartaPlex Simplex kits for nephrotoxicity research
ProcartaPlex Simplex kits are designed to be combinable with other Simplex kits so that you can create your own multiplex panel that utilizes Luminex xMAP technology for protein detection/quantitation. When combining multiple Simplex kits, only one buffer kit #EPX010-10420-901 (sold separately) is needed for each assay plate regardless of plex size.
View the complete list of ProcartaPlex panels
Mix & Match
Custom-blended panels deliver results tailored to your choice of targets. Simply provide your desired species, sample type, and instrument for use. Then select from our list of analytes and we will formulate a user-defined panel that is supplied with all the necessary reagents to perform the assay.
Related products and resources
Luminex Assays and equipment
Quantigene multiplex gene expression assays
Multiplex up to 80 RNA targets from a single biological sample.
Luminex Instruments
Explore the different Luminex systems: Luminex 200, FLEXMAP3D, and INTELLIFLEX models, which are all compatible with Invitrogen Luminex Assays.
Single analyte assays
ProQuantum High Sensitivity Immunoassays
Detect very low levels of proteins using as little as 1–5 μL of sample.
Invitrogen ELISA Kits
Quantitate single analytes with confidence with highly verified Invitrogen ELISA kits.
*FDA guidance for nephrotoxicity biomarkers: https://www.fda.gov/media/135310/download and https://www.fda.gov/media/87781/download
For Research Use Only. Not for use in diagnostic procedures.